Menu

Home / For Visitors / 2025 Exhibitor Product / Carfilzomib injectable 10mg/30mg/60mg

Carfilzomib injectable 10mg/30mg/60mg

Category: Pharmaceutical

Exhibitor: ORIENT EUROPHARMA CO., LTD.

Booth No: M426

Characteristic

The generic drug Carfilzomib (brand name Kyprolis®) is a second-generation proteasome inhibitor. Its mechanism of action involves irreversible and specific binding to the N-terminal threonine-containing active site of the 20S proteasome, functioning primarily as a targeted therapy for multiple myeloma. Kyprolis® was approved by the FDA in July 2012 and by the TFDA in August 2018. Currently, there is no generic version of this drug available on the Taiwan market.

Other Products

Products you may be interested in

Highest Rated Products

TOP